| 摘要: |
| 目的:评价儿童腺病毒呼吸道感染抗病毒用药的不合理性及影响因素。方法:纳入2020-2024 年我院622 例腺病毒呼吸
道感染住院患儿。按是否接受抗病毒治疗及用药合理性分组,比较组间差异,并通过logistic 回归分析抗病毒用药和不合理用
药的影响因素。结果:388 例(62. 4%)接受抗病毒治疗,262 例(67. 5%)用药不合理,包含超适应证(149 例,38. 4%)、给药途径
不适宜(28 例,7. 2%)、剂量不适宜(67 例,17. 3%) 和超疗程(18 例,4. 6%)。合并EB 病毒感染( OR = 27. 09,95%CI 9. 53 ~
77. 06)和热程≥1 周(OR=1. 94,95%CI 1. 09~3. 45)是应用抗病毒药物治疗的独立危险因素。合并EB 病毒感染( OR= 4. 69,
95%CI 1. 50~14. 70)、抗DNA 病毒药物(OR= 5. 44,95%CI 1. 90~15. 56) 及使用≥2 种抗病毒药物( OR = 4. 73,95%CI 2. 07~
10. 83)是不合理用药的独立危险因素。结论:儿童腺病毒呼吸道感染抗病毒用药合理性偏低,合并EB 病毒感染及长热程可能
导致过度治疗。 |
| 关键词: 儿童 抗病毒 合理用药 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2026.07.013 |
|
| 基金项目: |
|
| Irrational Antiviral Medication for Children with Adenovirus Respiratory Tract Infection and InfluencingFactors |
| Nie Hongmei, Tang Wei, Fan Yinghong, Yao Haibo, Ai Tao |
| ((Affiliated Women and Children’s Hospital of the Medical College
of University of Electronic Science and Technology of China, Chengdu Women and Children’s Center Hospital, Chengdu 610091, China)) |
| Abstract: |
| Objective: To evaluate the rationality of antiviral medication for children with adenovirus respiratory tract infection and
influencing factors. Methods: Totally 622 hospitalized children with adenovirus respiratory tract infection in our hospital from 2020 to
2024 were enrolled. The children were divided into two groups according to whether they were treated with antiviral therapy and the
rationality of medication. And logistic regression analysis was used to identify factors influencing the use of antiviral medication and
inappropriate medication. Results: Totally 388 cases (62. 4%) received antiviral therapy, and 262 cases (67. 5%) received
inappropriate treatment, including off-label indications (149 cases, 38. 4%), inappropriate route of administration (28 cases, 7. 2%),
inappropriate dosage (67 cases, 17. 3%), and off-label treatment course (18 cases, 4. 6%). Co-infection with EB virus (OR=27. 09,
95% CI 9. 53 to 77. 06) and fever duration of ⩾1 week (OR=1. 94, 95% CI 1. 09 to 3. 45) were independent risk factors for antiviral
therapy. Co-infection with EB virus (OR=4. 69, 95% CI 1. 50 to 14. 70), drugs targeting DNA viruses (OR=5. 44, 95% CI 1. 90 to 15. 56), and use of ⩾2 kinds of antiviral drugs (OR=4. 73, 95% CI 2. 07 to 10. 83) were independent risk factors for inappropriate
medication. Conclusion: The rationality of antiviral medication for children with adenovirus respiratory tract infection is relatively low.
Co-infection with EB virus and a long duration of disease may lead to over-treatment. |
| Key words: children antiviral rational medication |
